首页> 外国专利> METHODS AND KITS FOR PREDICTING THE RISK OF HAVING OR DEVELOPPING HEPATOCELLULAR CARCINOMA IN PATIENTS SUFFERING FROM CIRRHOSIS

METHODS AND KITS FOR PREDICTING THE RISK OF HAVING OR DEVELOPPING HEPATOCELLULAR CARCINOMA IN PATIENTS SUFFERING FROM CIRRHOSIS

机译:预测肝硬化患者肝细胞癌发生或发展风险的方法和试剂盒

摘要

Plasma levels of different sub-populations of microvesicles (endothelial, leukocyte, platelet and hepatocyte) were measured by flow cytometry or ELISA / filtration on blood samples from 125 patients with cirrhosis, for which 36 of them were diagnosed with HCC at inclusion. The inventors show that the levels of microvesicles of endothelial origin (CD62E +) could predict the occurrence of HCC in patients with cirrhosis. Therefore the present invention relates to a method for determining whether a patient suffering from cirrhosis is at risk of having or developing hepatocellular carcinoma comprising determining the level of endothelial-derived microvesicles (e.g. by flow cytometry) in a blood sample obtained from the patient.
机译:通过流式细胞仪或ELISA /过滤法对125例肝硬化患者的血样进行了不同的微泡亚群(内皮,白细胞,血小板和肝细胞)的血浆水平测定,其中36例被诊断为肝癌。发明人表明,内皮源微泡(CD62E +)的水平可以预测肝硬化患者中HCC的发生。因此,本发明涉及一种确定患有肝硬化的患者是否有罹患或发展成肝细胞癌的风险的方法,该方法包括确定从该患者获得的血液样品中内皮衍生的微囊泡的水平(例如通过流式细胞仪)。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号